Galafold

Active Ingredient(s): Migalastat Hydrochloride
FDA Approved: * August 10, 2018
Pharm Company: * AMICUS THERAPEUTICS US INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Galafold Overview

Migalastat (or 1-deoxygalactonojirimycin; trade names Galafold and formerly Amigal) is a drug for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) assigned it orphan drug status in 2004,[1] and the European Committee for Medicinal Products for Human Use (CHMP) followed in 2006. The European Commission approved the drug in May 2016.[2] Contents 1 Medical uses 2 Adverse...

Read more Galafold Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Migalastat

Recent Galafold Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Migalastat Hydrochloride
  • Capsule: 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Migalastat Hydrochloride or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 24 September 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA